These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

324 related articles for article (PubMed ID: 31711124)

  • 1. REToma: a cancer subtype with a shared driver oncogene.
    Kohno T; Tabata J; Nakaoku T
    Carcinogenesis; 2020 Apr; 41(2):123-129. PubMed ID: 31711124
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Precision Targeted Therapy with BLU-667 for
    Subbiah V; Gainor JF; Rahal R; Brubaker JD; Kim JL; Maynard M; Hu W; Cao Q; Sheets MP; Wilson D; Wilson KJ; DiPietro L; Fleming P; Palmer M; Hu MI; Wirth L; Brose MS; Ou SI; Taylor M; Garralda E; Miller S; Wolf B; Lengauer C; Guzi T; Evans EK
    Cancer Discov; 2018 Jul; 8(7):836-849. PubMed ID: 29657135
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Selective RET kinase inhibition for patients with RET-altered cancers.
    Subbiah V; Velcheti V; Tuch BB; Ebata K; Busaidy NL; Cabanillas ME; Wirth LJ; Stock S; Smith S; Lauriault V; Corsi-Travali S; Henry D; Burkard M; Hamor R; Bouhana K; Winski S; Wallace RD; Hartley D; Rhodes S; Reddy M; Brandhuber BJ; Andrews S; Rothenberg SM; Drilon A
    Ann Oncol; 2018 Aug; 29(8):1869-1876. PubMed ID: 29912274
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rearranged-in-transfection inhibitors: emerging agnostic targeted therapies for solid tumors.
    Saleh K; Felefly T; Khalife N; Kourie HR
    Pharmacogenomics; 2021 Apr; 22(5):247-250. PubMed ID: 33754802
    [No Abstract]   [Full Text] [Related]  

  • 5. Pralsetinib: First Approval.
    Markham A
    Drugs; 2020 Nov; 80(17):1865-1870. PubMed ID: 33136236
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of RET kinase inhibitors for targeted cancer therapy.
    Mologni L
    Curr Med Chem; 2011; 18(2):162-75. PubMed ID: 21110809
    [TBL] [Abstract][Full Text] [Related]  

  • 7. RET fusions in solid tumors.
    Li AY; McCusker MG; Russo A; Scilla KA; Gittens A; Arensmeyer K; Mehra R; Adamo V; Rolfo C
    Cancer Treat Rev; 2019 Dec; 81():101911. PubMed ID: 31715421
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of RET protein-tyrosine kinase inhibitors in the treatment RET-driven thyroid and lung cancers.
    Roskoski R; Sadeghi-Nejad A
    Pharmacol Res; 2018 Feb; 128():1-17. PubMed ID: 29284153
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Systematic Analysis of Tyrosine Kinase Inhibitor Response to RET Gatekeeper Mutations in Thyroid Cancer.
    Meng S; Wu H; Wang J; Qiu Q
    Mol Inform; 2016 Oct; 35(10):495-505. PubMed ID: 27712045
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Research Progress of Fusion Genes RET in Non-small Cell Lung Cancer].
    Zheng Y; Jiang W; Chen D; Li Y; Dai L; Huang L; Wang M
    Zhongguo Fei Ai Za Zhi; 2021 Aug; 24(8):591-597. PubMed ID: 34120433
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hallmarks of RET and Co-occuring Genomic Alterations in
    Adashek JJ; Desai AP; Andreev-Drakhlin AY; Roszik J; Cote GJ; Subbiah V
    Mol Cancer Ther; 2021 Oct; 20(10):1769-1776. PubMed ID: 34493590
    [TBL] [Abstract][Full Text] [Related]  

  • 12. RET fusions in non-small-cell lung cancer: an emerging target reshaping the treatment paradigm.
    Saleh K; Khalife N; Felefly T
    Future Oncol; 2021 Apr; 17(12):1445-1448. PubMed ID: 33573417
    [No Abstract]   [Full Text] [Related]  

  • 13. Antitumor activities of the targeted multi-tyrosine kinase inhibitor lenvatinib (E7080) against RET gene fusion-driven tumor models.
    Okamoto K; Kodama K; Takase K; Sugi NH; Yamamoto Y; Iwata M; Tsuruoka A
    Cancer Lett; 2013 Oct; 340(1):97-103. PubMed ID: 23856031
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ponatinib is a potent inhibitor of wild-type and drug-resistant gatekeeper mutant RET kinase.
    Mologni L; Redaelli S; Morandi A; Plaza-Menacho I; Gambacorti-Passerini C
    Mol Cell Endocrinol; 2013 Sep; 377(1-2):1-6. PubMed ID: 23811235
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Selpercatinib.
    Am J Health Syst Pharm; 2020 Oct; 77(22):1818-1821. PubMed ID: 32930710
    [No Abstract]   [Full Text] [Related]  

  • 16. Emergence of Resistant Clones in Medullary Thyroid Cancer May Not Be Rescued by Subsequent Salvage Highly Selective Rearranged During Transfection-Inhibitor Therapy.
    Bruce JY; Bible KC; Chintakuntlawar AV
    Thyroid; 2021 Feb; 31(2):332-333. PubMed ID: 32664802
    [No Abstract]   [Full Text] [Related]  

  • 17. In vitro transforming potential, intracellular signaling properties, and sensitivity to a kinase inhibitor (sorafenib) of RET proto-oncogene variants Glu511Lys, Ser649Leu, and Arg886Trp.
    Prazeres H; Couto JP; Rodrigues F; Vinagre J; Torres J; Trovisco V; Martins TC; Sobrinho-Simões M; Soares P
    Endocr Relat Cancer; 2011 Aug; 18(4):401-12. PubMed ID: 21551259
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analysis of Cell-Free DNA from 32,989 Advanced Cancers Reveals Novel Co-occurring Activating
    Rich TA; Reckamp KL; Chae YK; Doebele RC; Iams WT; Oh M; Raymond VM; Lanman RB; Riess JW; Stinchcombe TE; Subbiah V; Trevarthen DR; Fairclough S; Yen J; Gautschi O
    Clin Cancer Res; 2019 Oct; 25(19):5832-5842. PubMed ID: 31300450
    [TBL] [Abstract][Full Text] [Related]  

  • 19. RET fusion gene: translation to personalized lung cancer therapy.
    Kohno T; Tsuta K; Tsuchihara K; Nakaoku T; Yoh K; Goto K
    Cancer Sci; 2013 Nov; 104(11):1396-400. PubMed ID: 23991695
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ONC201 Shows Potent Anticancer Activity Against Medullary Thyroid Cancer via Transcriptional Inhibition of
    Bagheri-Yarmand R; Dadu R; Ye L; Shiny Jebaraj Y; Martinez JA; Ma J; Tarapore RS; Allen JE; Sherman SI; Williams MD; Gagel RF
    Mol Cancer Ther; 2021 Apr; 20(4):665-675. PubMed ID: 33536187
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.